BridgeBio Oncology Therapeutics Inc.

BBOT | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.66

-$0.11 (-2.31%)

At close: Sep 21, 2026, 4:00 PM ET

$4.58

-$0.08 (-1.72%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.31%

(1D)

Rating

Updated: Aug 27, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $373.3M

1D Range

4.60 4.73

52W Range

4.59 14.87

Valuation (TTM)

PE -0.01

PB 1.16

EV/EBITDA -0.77

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target $19

Cash Flow

FCF Yield -51.9%

SBC Adj. FCF Yield -54.6%

SBC Impact -5.3%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -149.5% | N/A

FCF 3Y | 5Y -104.1% | N/A

Returns

ROA -48.3%

ROE -46.9%

ROIC -61.1%

Financial Health

Net Cash

$223.2M

Current Ratio 4.69

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinosit...

Sector Healthcare

Industry Biotechnology

Employees 88

IPO Date Aug 11, 2025

Website bbotx.com

Fiscal Year January - December

Full Company Profile

Latest News

8 months ago · seekingalpha.com

BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$20

Upside

+329.18%

Buy (8)

Hold (0)

Sell (0)

Analyst Details ➞